<DOC>
	<DOCNO>NCT00327314</DOCNO>
	<brief_summary>The protocol aim reduce transplant toxicity mortality patient multiple myeloma .</brief_summary>
	<brief_title>Non-Myeloablative Allogeneic Transplantation From Unrelated Donors Multiple Myeloma</brief_title>
	<detailed_description>Primary end point engraftment non-relapse mortality . Secondary end point disease response , overall survival , progression event free survival . Patient eligibility criterion . Inclusion criterion include : - Diagnosis Durie-Salmon stage IIA-IIIB multiple myeloma - Age &gt; 18 ≤ 65 year start donor search - Presence concurrent co-morbidities preclude myeloablative conditioning refusal undergo conventional allogeneic transplant - Capacity give inform consent Exclusion criterion include : - Age &gt; 65 year - Karnofsky performance status score &lt; 60 % - Progressive disease stable disease less three month - Central nervous system ( CNS ) involvement - Left ventricular ejection fraction &lt; 35 % symptomatic heart failure - Poorly control hypertension - Pulmonary dysfunction diffuse capacity carbon monoxide ( DLCO ) &lt; 40 % and/or need continuous oxygen supplementation - Abnormal liver disease serum bilirubin great twice normal SGOT and/or SGPT great four time upper limit normal - HIV positive patient - Pregnancy - Refusal use contraceptive technique 12 month follow treatment Informed consent obtain study registration patient accord Institutional Review Boards participate center . The study conduct accord Declaration Helsinki .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Diagnosis DurieSalmon stage IIAIIIB multiple myeloma Age &gt; 18 ≤ 65 year start donor search Presence concurrent comorbidities preclude myeloablative conditioning refusal undergo conventional allogeneic transplant Capacity give inform consent Age &gt; 65 year Karnofsky performance status score &lt; 60 % Progressive disease stable disease less three month Central nervous system involvement Left ventricular ejection fraction &lt; 35 % symptomatic heart failure Poorly control hypertension Pulmonary dysfunction diffuse capacity carbon monoxide ( DLCO ) &lt; 40 % and/or need continuous oxygen supplementation Abnormal liver disease serum bilirubin great twice normal SGOT and/or SGPT great four time upper limit normal HIV positive patient Pregnancy Refusal use contraceptive technique 12 month follow treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2006</verification_date>
</DOC>